Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Although antagonism of mesolimbic dopamine D(2) receptors by neuroleptics such as haloperidol attenuates positive symptoms of schizophrenia, a significant population of "resistant" patients fails to respond while negative and cognitive symptoms are little modified. Furthermore, concomitant blockade of striatal D(2) receptors is associated with extrapyramidal motor side effects. The superior "atypical" antipsychotic profile of clozapine appears to reside in its broad pattern of interaction with D(2) receptors and a diversity of other monoaminergic sites. In this regard, serotonergic mechanisms are of particular relevance both in view of their modulation of dopaminergic transmission and their key role in the control of mood, cognition, and motor behavior. While most attention has focused on potential advantages of preferential 5-HT(2A) versus D(2) receptor blockade, 5-HT(1A) receptors likewise represent a valid target for improved antipsychotic agents. In this regard, rather than selective agents, ligands interacting with both 5-HT(1A) and D(2) receptors appear of interest. A modest level of efficacy appears optimal, that is, sufficient to engage highly sensitive 5-HT(1A) autoreceptors while blocking their low-sensitivity postsynaptic counterparts. Such a profile may counter negative and cognitive symptoms, improve mood, diminish extrapyramidal 5-HT(1A) motor side effects, and, perhaps, enhance efficacy in refractory patients. Notably, "partial agonist" properties of clozapine at 5-HT(1A) receptors may contribute to its distinctive functional profile. However, notwithstanding this compelling body of experimental data, clinical studies of antipsychotics interacting with 5-HT(1A) receptors are required to establish their genuine pertinence to the-hopefully improved-treatment of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of central 5-HT receptors and their function
Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,161
Psychopharmacology: The Fourth Generation of Progress
Green, A. I. (1996) · Psychiatric Services · doi:10.1176/ps.47.3.312 · Cited by 1,145
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Sargent, P. A., Kjaer, K. H., Bench, C. J., Rabiner, E. A., Messa, C., Meyer, J., Gunn, R. N., Grasby, P. M., & Cowen, P. J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.2.174 · Cited by 642
Meneses, A. (1999) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00067-6 · Cited by 475
The Role of Serotonin in Schizophrenia
Bleich, A., Brown, S.-L., Kahn, R., & van Praag, H. M. (1988) · Schizophrenia Bulletin · doi:10.1093/schbul/14.2.297 · Cited by 371
Dopamine, the prefrontal cortex and schizophrenia
Knable, M. B., & Weinberger, D. R. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100205 · Cited by 303
Schreiber, R., Brocco, M., Audinot, V, Gobert, A., Veiga, S., & Millan, M. J. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09485-6 · Cited by 300
Self-citationBurnet, P. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00053-x · Cited by 286
The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour
Steckler, T., & Sahgal, A. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(94)00157-b · Cited by 281
Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics
Miczek, K. A., Weerts, E. M., Vivian, J. A., & Barros, H. M. (1995) · Psychopharmacology · doi:10.1007/bf02245590 · Cited by 275
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237 · cited 3×
“…to potent and slowly dissociating " inverse agonists " , such as haloperidol, may less markedly and durably perturb basal dopaminergic activity (Seeman and Tallerico , 1999; Kapur et al., 2000); 2) partial D 2 /D 3 receptor agonists permitting dual presynaptic (via autoreceptors) and…”
Millan, M. J., Lejeune, F., & Gobert, A. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400202 · Cited by 231
Self-citationFrancis, P. T., Sims, N. R., Procter, A. W., & Bowen, D. M. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13381.x · Cited by 231
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study
Newman-Tancredi, A., Gavaudan, S., Conte, C., Chaput, C., Touzard, M., Verrièle, L., Audinot, V., & Millan, M. J. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00483-x · Cited by 227
Self-citationDeutch, A. Y. (1992) · Advances in Neuroscience and Schizophrenia · doi:10.1007/978-3-7091-9211-5_5 · Cited by 221
New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine
Brunello, N. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00068-o · Cited by 191
Alterations in the cortical serotonergic system in schizophrenia: A postmortem study
Gurevich, E. V., & Joyce, J. N. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00321-1 · Cited by 176
Burnet, P. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(96)00124-6 · Cited by 174
Ichikawa, J., & Meltzer, H. Y. (1999) · European Archives of Psychiatry and Clinical Neurosciences · doi:10.1007/pl00014190 · Cited by 160
Schreiber, R., & de Vry, J. (1993) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(93)90034-p · Cited by 158
Pharmacologic strategies for augmenting cognitive performance in schizophrenia
Friedman, J. I., Temporini, H. D., & Davis, K. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00287-x · Cited by 150
Millan, M. J., Brocco, M., Gobert, A., Joly, F., Bervoets, K., Rivet, J. ‐., Newman‐Tancredi, A., Audinot, V., & Maurel, S. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00858.x · Cited by 139
Self-citationAttenuation of haloperidol‐induced catalepsy by a 5‐HT2C receptor antagonist
Reavill, C. A., Kettle, A., Holland, V. A., Riley, G. J., & Blackburn, T. P. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702350 · Cited by 133
Cognition, schizophrenia, and the atypical antipsychotic drugs
Meltzer, H. Y., Park, S., & KESSLER, R. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13591 · Cited by 132
Effects of atypical antipsychotic agents on social behavior in rodents
Corbett, R., Hartman, H. B., Kerman, L. L., Woods, A. T., Strupczewski, J. T., Helsley, G. C., Conway, P. C., & Dunn, R. W. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90079-9 · Cited by 126
Ichikawa, J., & Meltzer, H. Y. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02346-x · Cited by 118
Azmitia, E. C., Rubinstein, V. J., Strafaci, J. A., Rios, J. C., & Whitaker‐Azmitia, P. M. (1995) · Brain Research · doi:10.1016/0006-8993(95)00051-q · Cited by 118
Adverse Effects of Antipsychotic Agents
Owens, D. G. C. (1996) · Drugs · doi:10.2165/00003495-199651060-00001 · Cited by 104
Lahti, A. C., Weiler, M. A., Corey, P. K., Lahti, R. A., Carlsson, A., & Tamminga, C. A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00030-9 · Cited by 104
Sipes, T. E., & Geyer, M. A. (1995) · Psychopharmacology · doi:10.1007/bf02245096 · Cited by 103
Cognitive deficit in schizophrenia and its neurochemical basis
Breier, A. F. (1999) · The British Journal of Psychiatry · doi:10.1192/s0007125000293604 · Cited by 87
Sprouse, J. S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00057-3 · Cited by 82
Garza, R. D. L., & Cunningham, K. A. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35331-5 · Cited by 81
Knockout Mice Reveal Opposite Roles for Serotonin 1A and 1B Receptors in Prepulse Inhibition
Dulawa, S. C. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00164-5 · Cited by 80
Ichikawa, J., Kuroki, T., Kitchen, M. T., & Meltzer, H. Y. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00624-9 · Cited by 78
The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat
Cassaday, H. J., Hodges, H., & Gray, J. A. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700110 · Cited by 74
5HT Antagonists Attenuate MK801-Impaired Radial Arm Maze Performance in Rats
Boast, C. A., Bartolomeo, A. C., Morris, H., & Moyer, J. A. (1999) · Neurobiology of Learning and Memory · doi:10.1006/nlme.1998.3886 · Cited by 72
Millan, M. J., Gobert, A., Newman‐Tancredi, A., Audinot, V., Lejeune, F., Rivet, J., Cussac, D., Nicolas, J., Müller, O., & Lavielle, G. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37731-6 · Cited by 65
Self-citationRiad, M., Emerit, M. B., & Hamon, M. (1994) · Developmental Brain Research · doi:10.1016/0165-3806(94)90167-8 · Cited by 58
Assié, M., Cosi, C., & Koek, W. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01207-7 · Cited by 55
The Neurochemistry of Prion Diseases
DeArmond, S. J., & Prusiner, S. B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09792.x · Cited by 50
Slater, P., Doyle, C. A., & Deakin, J. F. W. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050060 · Cited by 47
Carli, M., Balducci, C., Millan, M. J., Bonalumi, P., & SAMANIN, R. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702915 · Cited by 38
Self-citationHerges, S., & TAYLOR, D. A. H. B. (1999) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900058 · Cited by 27
Evenden, J. L. (1992) · Psychopharmacology · doi:10.1007/bf02245491 · Cited by 18
Fernández‐Espejo, E., & Gil, E. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00242-4 · Cited by 11
Cited by
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Self-citationSerotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
Alex, K. D., & Pehek, E. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.004 · Cited by 658
Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 591
Metadata
- Authors
- Millan, M. J.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2000-12
- Volume
- 295
- Issue
- 3
- Pages
- 853-861
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1927413935
- Cited by
- 287
- References
- 47
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.